Cytek Biosciences, Inc. (CTKB)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 93 | 128 | 164 | 193 | 200 | 201 | 207 | 209 |
| Operating profit | $m | -40 | -45 | ||||||
| Net profit | $m | 19 | 3 | 3 | -12 | -6 | -67 | -81 | -44 |
| EPS reported | $ | -0.52 | -0.62 | ||||||
| Operating cashflow per share | $ | -0.04 | -0.05 | ||||||
| Capex per share | $ | 0.03 | 0.05 | ||||||
| FCF per share | $ | -0.07 | -0.09 | ||||||
| Free cash flow | $m | -9 | -12 | ||||||
| Net debt | $m | -255 | -249 | ||||||
| Book value equity | $m | 342 | 322 | ||||||
| Book value per share | $ | 2.68 | 2.49 | ||||||
| Number of shares | m | 127.75 | 129.46 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.89 | 2.00 | ||||||
| P/S LTM | x | 3.20 | 3.12 | ||||||
| P/FCF LTM | x | -73.56 | -53.41 | ||||||
| EV/EBITDA LTM | x | -33.23 | -21.29 | ||||||
| EV/Sales LTM | x | 2.87 | 2.71 | ||||||
| Earnings Yield LTM | % | -10.31% | -13.24% | ||||||
| FCF Yield | % | -1.36% | -1.87% | ||||||
| Quality | |||||||||
| ROE | % | -19.47% | -23.53% | ||||||
| ROIC | % | -10.28% | -11.90% | ||||||
| Operating margin | % | -20.04% | -21.60% | ||||||
| Gross margin | % | +51.84% | +53.23% | ||||||
| FCF/Sales | % | -4.35% | -5.84% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +0.52% | +3.12% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.37 | -0.46 | ||||||
| Net Debt/EBITDA | x | 3.86 | 1.75 | ||||||
| EBIT/Net interest | x | -85.20 | -25.34 | ||||||
| Net debt/market cap | % | +1.06% | +1.59% | ||||||
| Net debt/Equity | x | -0.75 | -0.77 | ||||||
| Gross debt/equity | x | 0.07 | 0.08 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free